ASCO 2025 | Reforming the treatment landscape in melanoma with T-cell therapies
Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, shares his insight into the emerging T-cell therapies for patients with melanoma and their impact on the treatment landscape. The potentially curative treatments are currently undergoing Phase III testing with results expected in the coming years that will transform the standard of care for patients with melanoma. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What is the potential to change the treatment landscape in melanoma? I think that they have the potential to change the treatment landscape in melanoma because they potentially are for a cure, which is different from all the small molecules we are testing. And that applies both to tumor-infiltrating lymphocytes but also to T-cell receptor-modified T-cells. All of these approaches are now undergoing Phase III testing...
What is the potential to change the treatment landscape in melanoma? I think that they have the potential to change the treatment landscape in melanoma because they potentially are for a cure, which is different from all the small molecules we are testing. And that applies both to tumor-infiltrating lymphocytes but also to T-cell receptor-modified T-cells. All of these approaches are now undergoing Phase III testing. So it’s just a matter of one or two years to see the first results and then I think we will really have new standards for the treatment of patients with melanoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
